The first quarter of 2024 has brought to light several notable shifts in the healthcare value chain, presenting both new challenges as well as fresh growth opportunities.
Providers have witnessed robust growth in non-Covid patient activity and have benefited from increased reimbursements due to several factors, including higher rates. Conversely, Payors are grappling with significant challenges such as reduced segment enrollment and higher Medical Loss Ratios (MLRs). Amidst these market and competitive dynamics, the “Lower Costs, More Transparency Act” is making its way through Congress, potentially heralding transformative changes if passed.
In our new quarterly report, HealthscapeRX, we examine how a slew of competitive, dynamic, and regulatory forces are impacting both Providers and Payors.
